Preventing the exacerbation of COVID-19
respiratory failure, exacerbations
RESPIRATORY FAILURE
Kaplan–Meier estimates of the cumulative incidence of dexamethasone treatment due to COVID-19 exacerbations by day 8 were 42.9% in the control group (95% CI 7.6% to 75.7%), 14.3% in the demeclocycline 150 mg group (95% CI 0.5% to 49.1%), and 40.0% in the demeclocycline 300 mg group (95% CI 3.1% to 78.6%) (Fig. (Kaplan–Meier estimates of the cumulative incidence of continuous oxygen therapy due to respiratory failure in COVID-19 by day 8 were 16.7% in the control group (95% CI 0.5% to 54.9%) and 0.0% in the demeclocycline treatment groups (Fig. Average changes in oxygen saturation measured by pulse oximetry (SpONegative conversion of saliva SARS-CoV-2 RNA levels on day 8.Changes in and change rates of T cells from day 1 to day 8 of the study treatment.Demeclocycline150 mgDemeclocycline300 mg